A Phase I/IIa open label single ascending dose study to assess safety and tolerability of regulatory T cells to promote discontinuation of tacrolimus monotherapy in liver transplant recipients - LiveTreg - LiveTreg
Latest Information Update: 28 Nov 2025
At a glance
- Drugs Tacrolimus (Primary) ; Cell therapies
- Indications Liver transplant rejection
- Focus Adverse reactions
- Acronyms LiveTreg
Most Recent Events
- 28 Nov 2025 New trial record